431 related articles for article (PubMed ID: 31871155)
1. A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes.
Wang L; Smith BA; Balanis NG; Tsai BL; Nguyen K; Cheng MW; Obusan MB; Esedebe FN; Patel SJ; Zhang H; Clark PM; Sisk AE; Said JW; Huang J; Graeber TG; Witte ON; Chin AI; Park JW
Proc Natl Acad Sci U S A; 2020 Jan; 117(1):563-572. PubMed ID: 31871155
[TBL] [Abstract][Full Text] [Related]
2. Bladder Tumor Subtype Commitment Occurs in Carcinoma
Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
[TBL] [Abstract][Full Text] [Related]
3. Prognosis of early stage small cell bladder cancer is not always dismal.
Lim JH; Sundar S
ESMO Open; 2019; 4(6):e000559. PubMed ID: 31798978
[TBL] [Abstract][Full Text] [Related]
4. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
Davick JJ; Frierson HF; Smolkin M; Gru AA
Hum Pathol; 2018 Nov; 81():184-191. PubMed ID: 29969606
[TBL] [Abstract][Full Text] [Related]
6. Is there a role for maintenance therapy after platinum chemotherapy in bladder cancer in the era of immune therapy?
Rassy E; Assi T; Kattan J
Future Oncol; 2019 Dec; 15(34):3877-3879. PubMed ID: 31729240
[No Abstract] [Full Text] [Related]
7. TOX-expressing terminally exhausted tumor-infiltrating CD8
Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for genitourinary tumors.
Nakayama T; Kitano S
Int J Urol; 2019 Mar; 26(3):326-333. PubMed ID: 30710374
[TBL] [Abstract][Full Text] [Related]
9. Urothelial cancer stem cells and epithelial plasticity: current concepts and therapeutic implications in bladder cancer.
Garg M
Cancer Metastasis Rev; 2015 Dec; 34(4):691-701. PubMed ID: 26328525
[TBL] [Abstract][Full Text] [Related]
10. Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.
de Jong JJ; Stoop H; Nieboer D; Boormans JL; van Leenders GJLH
Histopathology; 2018 Dec; 73(6):983-989. PubMed ID: 30003574
[TBL] [Abstract][Full Text] [Related]
11. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
12. [Preneoplastic lesions and precursors of urothelial cancer].
Knüchel-Clarke R; Gaisa NT
Pathologe; 2016 Feb; 37(1):33-9. PubMed ID: 26811248
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic silencing of the dual-role signal mediator, ANGPTL4 in tumor tissues and its overexpression in the urothelial carcinoma microenvironment.
Hsieh HY; Jou YC; Tung CL; Tsai YS; Wang YH; Chi CL; Lin RI; Hung SK; Chuang YM; Wu SF; Li C; Shen CH; Chan MWY; Hsu CD
Oncogene; 2018 Feb; 37(5):673-686. PubMed ID: 29035390
[TBL] [Abstract][Full Text] [Related]
14. Small cell carcinoma of the bladder: the characteristics of molecular alterations, treatment, and follow-up.
Wang Y; Li Q; Wang J; Tong M; Xing H; Xue Y; Pan H; Huang C; Li D
Med Oncol; 2019 Oct; 36(12):98. PubMed ID: 31664527
[TBL] [Abstract][Full Text] [Related]
15. [Specific types of bladder cancer].
Bertz S; Hartmann A; Knüchel-Clarke R; Gaisa NT
Pathologe; 2016 Feb; 37(1):40-51. PubMed ID: 26782034
[TBL] [Abstract][Full Text] [Related]
16. Intravesical recurrence after bladder sparing treatment of small cell carcinoma of the bladder: Characteristics, treatment, and outcome.
van de Kamp M; Meijer R; Pos F; Kerst M; van Werkhoven E; van Rhijn B; Horenblas S; Bex A
Urol Oncol; 2018 Jun; 36(6):307.e1-307.e8. PubMed ID: 29580697
[TBL] [Abstract][Full Text] [Related]
17. Outside the box of immunotherapy - new hope for patients with advanced urothelial cancer.
Ullén A
Acta Oncol; 2019 Jul; 58(7):951-952. PubMed ID: 31232133
[No Abstract] [Full Text] [Related]
18. Role of Checkpoint Inhibition in Localized Bladder Cancer.
Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
[TBL] [Abstract][Full Text] [Related]
19. DNA copy number alterations and PPARG amplification in a patient with multifocal bladder urothelial carcinoma.
Conconi D; Panzeri E; Redaelli S; Bovo G; Volante M; Viganò P; Strada G; Dalprà L; Bentivegna A
BMC Res Notes; 2012 Oct; 5():607. PubMed ID: 23114535
[TBL] [Abstract][Full Text] [Related]
20. Trp53 Mutation in Keratin 5 (Krt5)-Expressing Basal Cells Facilitates the Development of Basal Squamous-Like Invasive Bladder Cancer in the Chemical Carcinogenesis of Mouse Bladder.
Masuda N; Murakami K; Kita Y; Hamada A; Kamada M; Teramoto Y; Sakatani T; Matsumoto K; Sano T; Saito R; Okuno Y; Ogawa O; Kobayashi T
Am J Pathol; 2020 Aug; 190(8):1752-1762. PubMed ID: 32339497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
